Inventor · disambiguated record
Jingrong Jean Cui
Also filed as: CUI JINGRONG · CUI JINGRONG J · CUI JINGRONG JEAN
46 granted patents·28 pending applications·574 citations·filing 2000–2025
98Inventor score
Top patents by PatentIndex Score
74 records- 0196US10246466B2Diaryl macrocycles as modulators of protein kinasesTP THERAPEUTICS INC·Filed 2017·Granted Apr 2, 2019·18 cites·17 claims
- 0296US9714258B2Diaryl macrocycles as modulators of protein kinasesTP THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·25 cites·22 claims
- 0395US11155563B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2021·Granted Oct 26, 2021·3 cites·3 claims
- 0495US10294242B2Diaryl macrocycle polymorphTP THERAPEUTICS INC·Filed 2016·Granted May 21, 2019·18 cites·20 claims
- 0595US8680111B2Macrocyclic derivatives for the treatment of diseasesPFIZER·Filed 2013·Granted Mar 25, 2014·54 cites·18 claims
- 0694US10745416B2Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Aug 18, 2020·4 cites·29 claims
- 0794US7858643B2Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitorsAGOURON PHARMA·Filed 2005·Granted Dec 28, 2010·28 cites·2 claims
- 0894US6610688B24-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitorsSUGEN INC·Filed 2000·Granted Aug 26, 2003·74 cites·22 claims
- 0993US10618912B2Diaryl macrocycles as modulators of protein kinasesTURNING POINT THERAPEUTICS INC·Filed 2018·Granted Apr 14, 2020·5 cites·19 claims
- 1093US8106197B2Aminoheteroaryl compounds as protein kinase inhibitorsCUI JINGRONG JEAN·Filed 2006·Granted Jan 31, 2012·48 cites·11 claims
- 1193US6677368B24-aryl substituted indolinonesSUGEN INC·Filed 2001·Granted Jan 13, 2004·72 cites·20 claims
- 1292US11142533B2Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2021·Granted Oct 12, 2021·2 cites·3 claims
- 1392US10689400B2Macrocycle kinase inhibitorsTURNING POINT THERAPEUTICS INC·Filed 2017·Granted Jun 23, 2020·7 cites·19 claims
- 1492US10316044B2Chiral diaryl macrocycles as modulators of protein kinasesTP THERAPEUTICS INC·Filed 2016·Granted Jun 11, 2019·18 cites·22 claims
- 1592US7230098B2Aminoheteroaryl compounds as protein kinase inhibitorsSUGEN INC·Filed 2004·Granted Jun 12, 2007·73 cites·15 claims
- 1691US12187739B2Diaryl macrocycle polymorphTURNING POINT THERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·1 cites·23 claims
- 1791US11981684B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2022·Granted May 14, 2024·1 cites·20 claims
- 1891US11286264B2Macrocyclic compounds and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2018·Granted Mar 29, 2022·4 cites·21 claims
- 1989US9133215B2Macrocyclic derivatives for the treatment of diseasesPFIZER·Filed 2014·Granted Sep 15, 2015·16 cites·18 claims
- 2089US8217057B2Polymorphs of a c-MET/HGFR inhibitorCUI JINGRONG JEAN·Filed 2006·Granted Jul 10, 2012·16 cites·10 claims
- 2187US7732604B2Triazolopyrazine derivativesPFIZER·Filed 2007·Granted Jun 8, 2010·11 cites·11 claims
- 2286US2025223298A1Diaryl macrocycle polymorphTURNING POINT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2385US11452725B2Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·1 cites·20 claims
- 2484US11634433B2Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·1 cites·17 claims
- 2584US6599902B25-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitorsSUGEN INC·Filed 2002·Granted Jul 29, 2003·21 cites·23 claims
- 2683US12404281B2Diaryl macrocycles as modulators of protein kinasesTURNING POINT THERAPEUTICS INC·Filed 2023·Granted Sep 2, 2025·0 cites·7 claims
- 2783US8916593B2Alkoxy-substituted 2-aminopyridines as ALK inhibitorsBUNNAGE MARK EDWARD·Filed 2011·Granted Dec 23, 2014·8 cites·5 claims
- 2882US8785632B2Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitorsCUI JINGRONG JEAN·Filed 2012·Granted Jul 22, 2014·5 cites·4 claims
- 2979US12310968B2Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2022·Granted May 27, 2025·0 cites·27 claims
- 3077US11291667B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2018·Granted Apr 5, 2022·1 cites·15 claims
- 3177US6635640B24-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitorsSUGEN INC·Filed 2001·Granted Oct 21, 2003·10 cites·13 claims
- 3277US2025375451A1Chiral diaryl macrocycles and uses thereofTURNING POINT THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3377US2022112213A1Diaryl macrocycles as modulators of protein kinasesTURNING POINT THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3475US9328096B2Tropomyosin-related kinase inhibitorsPFIZER·Filed 2015·Granted May 3, 2016·2 cites·21 claims
- 3575US2023322806A1Macrocycles for use in treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3675US2019233437A1Diaryl macrocycle polymorphTP THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3775US2021094974A1Diaryl macrocycle polymorphTURNING POINT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3874US6908930B24-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitorsSUGEN INC·Filed 2003·Granted Jun 21, 2005·6 cites·12 claims
- 3973US7053086B24-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitorsSUGEN INC·Filed 2003·Granted May 30, 2006·6 cites·12 claims
- 4072US7250417B2Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitorsSUGEN INC·Filed 2004·Granted Jul 31, 2007·6 cites·8 claims
- 4172US2022306652A1Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4271US11286265B2Macrocyclic compounds for treating diseaseTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·0 cites·15 claims
- 4371US7037909B2Tetracyclic compounds as c-Met inhibitorsSUGEN INC·Filed 2004·Granted May 2, 2006·5 cites·11 claims
- 4470US2020216465A1Diaryl macrocycles as modulators of protein kinasesTURNING POINT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4569US2024033266A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4667US7105562B2Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitorsSUGEN INC·Filed 2004·Granted Sep 12, 2006·3 cites·4 claims
- 4767US2023398119A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4864US2025353864A1Indazole containing macrocycles and their useBLOSSOMHILL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4963US11654145B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2020·Granted May 23, 2023·0 cites·30 claims
- 5063US2025074920A1Macrocyclic compounds and use as kinase inhibitorsBLOSSOMHILL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jingrong Jean Cui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →